الفهرس 
Outcome and prognostic factors of Hepatoblastoma at National Cancer Institute
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 198 |  |  |
| | | from | 198 | | |
Abstract
Purpose: hepatoblastoma is most common pediatric liver tumor, a huge progress has been made in management of this disease yet it remains a mystery in developing countries.Our study aimed to assess event free survival (EFS) and overall survival (OS) of de novo pediatric hepatoblastoma (HB) patients and their relation to different prognostic factors. Methods : This study is a combined retrospective and prospective study that was carried out at the National Cancer Institute, Egypt (NCI),and children cancer hospital Egypt(CCHE) during the period of 1/01/2013{u2013} 30/06/2016 using a modified version of the current COG protocol AHEP 0731 with a minimum of 6 months follow up.Results: The 3 years overall survival of our study group was 69.2% with a median survival of 23 months with a follow up period from 0.1 to 57 months and 95% confidence interval of (10-57).The 3 years EFS survival of our study group was 60.2%. Correlation of OS with different prognostic factors showed poor prognosis in presence of metastatic disease p value (0.025)LN enlargement( p value < 0.001) ,multifocal disease (p value 0.003 ), tumor involving both lobes( p value 0.046) and AFP level<100( p value 0.024) and good prognosis for those with young age p value( 0.032), PRETEXT stages I&II (p value 0.012)and those with AFP log reduction >1 after first 2 cycles of therapy(p value0.005). Correlation of EFS with different prognostic factors showed poor prognosis with LN enlargement( p value <0.001) ,multifocal disease (p value 0.005 ), PV thrombosis(p value <0.001) and AFP level<100 p value(0.044) and good prognosis for those with young age p value( 0.013), PRETEXT stages I&II (p value 0.034) and those with AFP log reduction >1 after first 2 cycles of therapy(p value0.010)